Technology


ADAPT® Tissue Engineering Process

CardioCel

The ADAPT® process is our platform technology.

ADAPT® renders bio-prosthetic tissue into a durable, bio-compatible tissue scaffold that allows the reparative healing processes to take place after implantation without any visible calcification. The resulting tissue bio-implants more closely mimic native tissue as the body recognises it as “self”.

CardioCel

The ADAPT® technology, when applied to xenograft tissues, produces unique implantable tissue scaffolds that are not only compatible with the human body, but most notably overcome many of the problems associated with existing tissue bio-implants currently in use.

About ADAPT®

CardioCel

More than a decade of step-by-step, published clinical validation

CardioCel

CardioCel®

The current focus is in the cardiovascular space, where our first tissue scaffold CardioCel® has demonstrated superior performance in both pre-clinical and clinical studies.

Patients in the first Phase II Clinical trial are now entering their 7th year without any reported adverse events after correction of simple and more complex congenital cardiac defects.

CardioCel® is now on the market and is being used by cardiac surgeons in key centres around the world. Uptake of CardioCel® is growing on a global scale, with increasing confidence being seen from within the cardiovascular community.

CardioCel Product

Production capacity of CardioCel® at our bio-manufacturing facility in Perth, Western Australia, can currently satisfy global demand for CardioCel®.

Future product development

Admedus has a pipeline of products currently in development where the ADAPT® technology can be applied to a number of surgical applications.

The technology has the potential for use in different clinical applications with bio-prosthetic substitute potential.